Key result
Remdesivir treatment during COVID-19 hospitalization was associated with lower odds of 30-day COVID-19-related readmission compared to no remdesivir (3.3% vs 4.2%; OR 0.78, 95% CI 0.75-0.80).
Why the study?
Reducing hospital readmission improves healthcare quality and costs, but remdesivir's effectiveness in reducing 30-day COVID-19-related readmissions during the Omicron era was unclear.
Does remdesivir reduce 30-day COVID-19-related readmission in adult patients hospitalized for COVID-19?
Cohort (n=210,586)
Yes
Does remdesivir reduce 30-day COVID-19-related readmission in adult patients hospitalized for COVID-19?
Odds Ratio: 0.78 (95% CI 0.75–0.8)
Absolute Event Rate: 3.3% vs 4.2%
Remdesivir treatment during COVID-19 hospitalization is associated with a significantly reduced risk of 30-day COVID-19-related readmission, including in vulnerable populations like the elderly and immunocompromised.
Remdesivir-associated lower readmission risk may inform discharge planning; leaves open need for randomized confirmation in Omicron-era populations.
BACKGROUND: Reducing hospital readmission offer potential benefits for patients, providers, payers, and policymakers to improve quality of healthcare, reduce cost, and improve patient experience. We investigated effectiveness of remdesivir in reducing 30-day coronavirus disease 2019 (COVID-19)-related readmission during the Omicron era, including older adults and those with underlying immunocompromising conditions. METHODS: This retrospective study utilized the US PINC AI Healthcare Database to identify adult patients discharged alive from an index COVID-19 hospitalization between December 2021 and February 2024. Odds of 30-day COVID-19-related readmission to the same hospital were compared between patients who received remdesivir vs those who did not, after balancing characteristics of the two groups using inverse probability of treatment weighting (IPTW). Analyses were stratified by maximum supplemental oxygen requirement during index hospitalization. RESULTS: Of 326 033 patients hospitalized for COVID-19 during study period, 210 586 patients met the eligibility criteria. Of these, 109 551 (52%) patients were treated with remdesivir. After IPTW, lower odds of 30-day COVID-19-related readmission were observed in patients who received remdesivir vs those who did not, in the overall population (3.3% vs 4.2%, respectively; odds ratio [95% confidence interval {CI}]: 0.78 [.75-.80]), elderly population (3.7% vs 4.7%, respectively; 0.78 [.75-.81]), and those with underlying immunocompromising conditions (5.3% vs 6.2%, respectively; 0.86 [.80-.92]). These results were consistent irrespective of supplemental oxygen requirements. CONCLUSIONS: Treating patients hospitalized for COVID-19 with remdesivir was associated with a significantly lower likelihood of 30-day COVID-19-related readmission across all patients discharged alive from the initial COVID-19 hospitalization, including older adults and those with underlying immunocompromising conditions.
No takes yet. Share an insight, caveat, or question.
Mozaffari et al. (2024) conducted a cohort in COVID-19 (n=210,586). Remdesivir vs. No remdesivir was evaluated on 30-day COVID-19-related readmission to the same hospital (OR 0.78, 95% CI 0.75-0.80). Remdesivir treatment during COVID-19 hospitalization was associated with lower odds of 30-day COVID-19-related readmission compared to no remdesivir (3.3% vs 4.2%; OR 0.78, 95% CI 0.75-0.80).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: